RecruitingPhase 2NCT06947993

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Sponsor

Novartis Pharmaceuticals

Enrollment

224 participants

Start Date

May 16, 2025

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis

Summary

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GHZ339 and a drug called Placebo for people with atopic dermatitis. The study is currently recruiting participants at 99 locations. People eligible for this study include aged 18 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGHZ339

GHZ339 administered at dose A, B, C and D

DRUGPlacebo

Matching placebo

Locations(99)

Novartis Investigative Site

Birmingham, Alabama, United States

Novartis Investigative Site

Birmingham, Alabama, United States

Novartis Investigative Site

Fort Smith, Arkansas, United States

Novartis Investigative Site

Fountain Valley, California, United States

Novartis Investigative Site

Los Angeles, California, United States

Novartis Investigative Site

Sacramento, California, United States

Novartis Investigative Site

Santa Ana, California, United States

Novartis Investigative Site

Santa Monica, California, United States

Novartis Investigative Site

Washington D.C., District of Columbia, United States

Novartis Investigative Site

Miami, Florida, United States

Novartis Investigative Site

Atlanta, Georgia, United States

Novartis Investigative Site

Macon, Georgia, United States

Novartis Investigative Site

Louisville, Kentucky, United States

Novartis Investigative Site

Brighton, Massachusetts, United States

Novartis Investigative Site

Troy, Michigan, United States

Novartis Investigative Site

Saint Joseph, Missouri, United States

Novartis Investigative Site

Brooklyn, New York, United States

Novartis Investigative Site

Arlington, Texas, United States

Novartis Investigative Site

Cypress, Texas, United States

Novartis Investigative Site

Dallas, Texas, United States

Novartis Investigative Site

Houston, Texas, United States

Novartis Investigative Site

San Antonio, Texas, United States

Novartis Investigative Site

Caba, Buenos Aires, Argentina

Novartis Investigative Site

Caba, Buenos Aires, Argentina

Novartis Investigative Site

Rosario, Santa Fe Province, Argentina

Novartis Investigative Site

Edmonton, Alberta, Canada

Novartis Investigative Site

Hamilton, Ontario, Canada

Novartis Investigative Site

Markham, Ontario, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Verdun, Quebec, Canada

Novartis Investigative Site

Guangzhou, Guangdong, China

Novartis Investigative Site

Shantou, Guangdong, China

Novartis Investigative Site

Changsha, Hunan, China

Novartis Investigative Site

Changchun, Jilin, China

Novartis Investigative Site

Hangzhou, Zhejiang, China

Novartis Investigative Site

Beijing, China

Novartis Investigative Site

Beijing, China

Novartis Investigative Site

Shanghai, China

Novartis Investigative Site

Plzen Bory, Czechia

Novartis Investigative Site

Prague, Czechia

Novartis Investigative Site

Prague, Czechia

Novartis Investigative Site

Prague, Czechia

Novartis Investigative Site

Brest, France

Novartis Investigative Site

Lille, France

Novartis Investigative Site

Lorient, France

Novartis Investigative Site

Paris, France

Novartis Investigative Site

Pierre-Bénite, France

Novartis Investigative Site

Reims, France

Novartis Investigative Site

Rouen, France

Novartis Investigative Site

Frankfurt am Main, Hesse, Germany

Novartis Investigative Site

Mainz, Rhineland-Palatinate, Germany

Novartis Investigative Site

Bad Bentheim, Germany

Novartis Investigative Site

Dresden, Germany

Novartis Investigative Site

Hamburg, Germany

Novartis Investigative Site

Heidelberg, Germany

Novartis Investigative Site

Magdeburg, Germany

Novartis Investigative Site

Münster, Germany

Novartis Investigative Site

Oldenburg, Germany

Novartis Investigative Site

Pécs, Baranya, Hungary

Novartis Investigative Site

Debrecen, Hajdu Bihar Megye, Hungary

Novartis Investigative Site

Budapest, Hungary

Novartis Investigative Site

Budapest, Hungary

Novartis Investigative Site

Szeged, Hungary

Novartis Investigative Site

Ancona, AN, Italy

Novartis Investigative Site

Cona, FE, Italy

Novartis Investigative Site

Nagoya, Aichi-ken, Japan

Novartis Investigative Site

Matsudo, Chiba, Japan

Novartis Investigative Site

Kawasaki, Kanagawa, Japan

Novartis Investigative Site

Yokohama, Kanagawa, Japan

Novartis Investigative Site

Habikino, Osaka, Japan

Novartis Investigative Site

Shinagawa Ku, Tokyo, Japan

Novartis Investigative Site

Fukuoka, Japan

Novartis Investigative Site

Kyoto, Japan

Novartis Investigative Site

Rotterdam, South Holland, Netherlands

Novartis Investigative Site

Utrecht, Netherlands

Novartis Investigative Site

Warsaw, Masovian Voivodeship, Poland

Novartis Investigative Site

Katowice, Poland

Novartis Investigative Site

Lodz, Poland

Novartis Investigative Site

Lublin, Poland

Novartis Investigative Site

Warsaw, Poland

Novartis Investigative Site

Bardejov, Slovakia

Novartis Investigative Site

Komárno, Slovakia

Novartis Investigative Site

Košice, Slovakia

Novartis Investigative Site

Košice, Slovakia

Novartis Investigative Site

Prešov, Slovakia

Novartis Investigative Site

Ansan, Gyeonggi-do, South Korea

Novartis Investigative Site

Seoul, South Korea

Novartis Investigative Site

Badalona, Barcelona, Spain

Novartis Investigative Site

Alicante, Spain

Novartis Investigative Site

Granada, Spain

Novartis Investigative Site

Las Palmas GC, Spain

Novartis Investigative Site

Madrid, Spain

Novartis Investigative Site

Madrid, Spain

Novartis Investigative Site

Pontevedra, Spain

Novartis Investigative Site

Kaohsiung City, Taiwan

Novartis Investigative Site

Taipei, Taiwan

Novartis Investigative Site

Taipei, Taiwan

Novartis Investigative Site

Dudley, West Midlands, United Kingdom

Novartis Investigative Site

Liverpool, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06947993

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

NCT006058781 location

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT0639791116 locations

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

NCT065994111 location

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

NCT076458204 locations